Nektar Therapeutics Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures
Nektar Therapeutics (NKTR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures of 5.89 million shares for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-04.
Discontinued › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod · last filed 2022-11-04
- Nektar Therapeutics share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2022-09-30 was 5.89M shares, a 1383.63% increase year-over-year.
- Nektar Therapeutics share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2022-06-30 was 85.00K shares, a 45.86% decline year-over-year.
- Nektar Therapeutics share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2022-03-31 was 22.00K shares, a 81.82% decline year-over-year.
- Nektar Therapeutics share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2021-09-30 was 397.00K shares, a 70.39% increase year-over-year.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 9 month |
|---|---|---|---|
| 2022-09-30 | 5.89M shares 10-Q · filed 2022-11-04 | 5.97M shares derived: sum of 2 quarters · filed 2022-11-04 | 6.02M shares 10-Q · filed 2022-11-04 |
| 2022-06-30 | 85.00K shares 10-Q · filed 2022-08-05 | 107.00K shares 10-Q · filed 2022-08-05 | |
| 2022-03-31 | 22.00K shares 10-Q · filed 2022-05-06 | ||
| 2021-09-30 | 397.00K shares 10-Q · filed 2022-11-04 | 554.00K shares derived: sum of 2 quarters · filed 2022-11-04 | 674.00K shares 10-Q · filed 2022-11-04 |
| 2021-06-30 | 157.00K shares 10-Q · filed 2022-08-05 | 278.00K shares 10-Q · filed 2022-08-05 | |
| 2021-03-31 | 121.00K shares 10-Q · filed 2022-05-06 | ||
| 2020-09-30 | 233.00K shares 10-Q · filed 2021-11-05 | 233.00K shares derived: sum of 2 quarters · filed 2021-11-05 | 282.00K shares 10-Q · filed 2021-11-05 |
| 2020-06-30 | 0.00 shares 10-Q · filed 2021-08-06 | 49.00K shares 10-Q · filed 2021-08-06 | |
| 2020-03-31 | 49.00K shares 10-Q · filed 2021-05-07 | ||
| 2011-09-30 | 331.48K shares 10-Q · filed 2011-11-04 | 595.39K shares derived: sum of 2 quarters · filed 2011-11-04 | 2.72M shares 10-Q · filed 2011-11-04 |
| 2011-06-30 | 263.91K shares 10-Q · filed 2011-08-05 | 2.39M shares 10-Q · filed 2011-08-05 | |
| 2010-09-30 | 560.32K shares 10-Q · filed 2011-11-04 | 1.28M shares derived: sum of 2 quarters · filed 2011-11-04 | 5.04M shares 10-Q · filed 2011-11-04 |
| 2010-06-30 | 718.23K shares 10-Q · filed 2011-08-05 | 4.48M shares 10-Q · filed 2011-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |